Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results tomorrow after market close. Here’s what to ...

A federal judge on Monday threw out a $96 million jury verdict against genetic testing company CareDX that rival Natera had ...

Natera Inc (NASDAQ:NTRA) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue ...

Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

We recently published a list of Joe DiMenna’s Stock Portfolio: Top 10 Stocks to Buy. In this article, we are going to take a ...

Natera (NTRA) announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services’ Molecular ...

Natera (NASDAQ:NTRA – Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ...

The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high- ...

Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

John Fesko, President and Chief Business Officer of Natera, Inc. (NASDAQ:NTRA), recently reported transactions involving the company's common stock. The company, now valued at $22.8 billion, has seen ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor ...

The test has met coverage requirements for use with patients with non-small cell lung cancer with resectable or unresectable disease in the surveillance setting.